News
U.S.-listed shares of Novo Nordisk fell sharply for a second straight day Wednesday, this time after Bank of America ...
July 29 (UPI) -- Novo Nordisk announced Tuesday that Mike Doustdar has been appointed as the company's new CEO. Doustdar ...
U.S.-listed shares of Novo Nordisk sank in premarket trading Tuesday after the Danish drugmaker cut its full-year outlook and ...
23h
Pharmaceutical Technology on MSNNovo Nordisk shares plummet as 2025 guidance is cut, overshadowing new CEOCEO-to-be Maziar Mike Doustdar will need to stem the company’s tumbling share price as market pressures intensify.
Key Points Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year. Eli Lilly's GLP-1 drugs may have more potential, but Novo Nordisk is ...
SourceL Finviz Novo Drama Hims & Hers Health slumped last week as Novo Nordisk ended the partnership with the online health and wellness platform to sell Wegovy, despite just forming a partnership.
Novo Nordisk A/S (NYSE: NVO) is one of the 10 best defensive stocks to buy in a volatile market. On July 7, the company received a significant boost in its proposed $2.34 billion investment in a ...
Trump's “big, beautiful bill” and frenetic tariff activity have fueled a lobbying gusher in the opening months of his term.
Hims & Hers Health partnered with Novo Nordisk earlier this year, only for that to unravel shortly afterward due to controversial practices around the sale of compounded drugs.
Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a maintenance fee in 2019.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results